From the webinar, "Learn How Genetic Testing Can Help Inform Your Neuropsychiatric Treatment Decisions," presented by Dr. Jay Lombard, Chief Scientific Officer of Genomind, LLC.
Dr. Lombard discusses scientific, clinical, and research aspects regarding the pharmacodynamic and pharmacokinetic genes in the Genecept™ Assay - genes that influence neurotransmitter activity and treatment plans for neuropsychiatric disorders. He discusses recent developments in the science of biomarkers for dopamine and serotonin, as well as genes that affect drug metabolism in the body.
The Genecept Assay is Genomind's proprietary genetic test that offers the possibility of "Personalized Medicine" in psychiatry. Clinicians may find this additional genetic information can lead to optimized treatment plans for individual patients.
Genomind is a company specializing in neuropsychiatric personalized medicine and was formed to facilitate the adoption of personalized medicine into psychiatry by providing genetic information to better understand the patient.
For more information, please visit our website at www.genomind.com.
Clipping is a handy way to collect important slides you want to go back to later.